Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2339${count})

  • Therapeutic Pipeline Program, 2020
    Photoreceptor-Directed Light Therapy in Parkinson’s Disease

    Study Rationale:    
    Non-motor symptoms including sleep disturbances are common and enormously impact quality of life in people with Parkinson’s disease (PD). Sleep disruption affects motor function...

  • Research Grant, 2020
    Investigating the Role of LRRK2 in Tau Pathogenesis

    Study Rationale:
    While most cases of Parkinson’s disease have no known genetic cause, a subset of Parkinson’s is caused by mutations in the leucine-rich repeat kinase 2 (LRRK2) gene. It is believed...

  • Biosample Use Program, 2020
    Relationship of Plasma Vitamin B12 and Homocysteine Levels with Outcomes in SURE-PD and STEADY-PD Trials

    Study Rationale:
    Vitamin B12 levels are lower in people with Parkinson’s disease. Our prior investigation showed that lower B12 levels were associated with more rapid worsening of gait and stability...

  • Biosample Use Program, 2020
    Metabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PD

    Study Rationale:
    Mutations in a gene called LRRK2 can cause Parkinson's disease but only a quarter to half of the people who carry one of these mutations will actually develop Parkinson’s in their...

  • Research Grant, 2020
    More Than Pretty Pictures: Ion Imaging of Lipid Content and Flux Kinetics in Models of Parkinson’s Disease

    Study Rationale:
    Glycosphingolipids are natural cellular fats. They are components of cellular membranes that fulfill multiple functional roles, from cell structure and transport to signaling. The...

  • Therapeutic Pipeline Program, 2020
    Developing TMEM175 Activators as Therapeutics for Parkinson's Disease

    Study Rationale:    
    Our aim is to develop a drug that will slow or stop the progression of Parkinson’s disease in patients who carry a mutation in the TMEM175 gene. The TMEM175 gene produces a...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.